Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

$RNAC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RNAC alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $RNAC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RNAC

DatePrice TargetRatingAnalyst
12/19/2024$42.00Buy
BTIG Research
8/6/2024Buy
TD Cowen
7/2/2024Outperform → Perform
Oppenheimer
6/4/2024$50.00Outperform
Oppenheimer
5/24/2024$40.00Buy
Mizuho
4/23/2024$2.00 → $54.00Buy
H.C. Wainwright
4/23/2024$39.00Outperform
Leerink Partners
More analyst ratings

$RNAC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cartesian Therapeutics Announces New Employment Inducement Grants

    FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company's common stock with an exercise price of $12.49, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were ap

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

    FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a clinica

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

    Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3 million cash, cash equivalents and restricted cash as of December 31, 2024 expected to support planned operations into mid-2027, including completion of planned Phase 3 AURORA trial FREDERICK, M

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RNAC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RNAC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RNAC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RNAC
SEC Filings

See more

$RNAC
Leadership Updates

Live Leadership Updates

See more
  • Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

    Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

    Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

    GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His deep experience in successfully advancing innovative therapies through all st

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RNAC
Financials

Live finance-specific insights

See more
  • Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

    Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observed through Month 12 in Phase 2b trial Safety profile consistent with previously reported data and continues to support outpatient administration Company to host conference call and webcast with key opinion leader today at 7:30 a.m. ET FREDERICK, Md., Dec. 03, 2024 (GLOB

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

    FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

    Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin

    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RNAC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more